Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
全站搜尋
:::

林裕誠 (Yu-Cheng Lin)

林裕誠(Yu-Cheng Lin)圖 複診掛號 初診掛號

[簡介]

  • 學歷
    • 國立台灣大學 醫學院醫學系 學士
    • 國立台灣大學 臨床醫學研究所 醫學博士
  • 經歷
    現職：
    • - 迄今 臺北榮民總醫院 兒童醫學部 主治醫師
    • - 迄今 臺北榮民總醫院 兒童胃腸科 科主任
    • - 迄今 台灣小兒消化醫學會 理事
    • - 迄今 中華民國肥胖研究學會 理事
    • - 迄今 兒童肝膽疾病防治基金會 董事
    • - 迄今 亞太APPSPGHAN科學委員會 委員
    • - 迄今 台灣兒科醫學會研究委員會 委員
    • - 迄今 台灣兒科醫學會 兒科消化學委員會 委員
    經歷：
    • - 亞東紀念醫院 小兒部 主治醫師
    • - 亞東紀念醫院 醫療事務處 處主任
    • - 亞東紀念醫院 小兒急診科 科主任
    • - 亞東紀念醫院 共同研究室 科主任
    • - 科技部生科司 婦幼醫學學門
  • 醫療專長
    1. 兒童青少年肥胖症、脂肪肝
    2. 兒童青少年腸胃道疾病：嘔吐、腹瀉、腹痛、便秘、出血等
    3. 幼兒生長遲緩、嬰幼兒營養諮詢
    4. 兒童青少年肝膽疾病防治
    5. 腹部超音波、胃鏡、大腸鏡、肝纖維化掃描Fibroscan
  • 證照
    兒科專科醫師 兒科消化學次專科醫師 肥胖症專科醫師 青少年醫學次專科醫師 消化系內視鏡專科醫師

[著作]

  1. Lin YC, Liao FM, Chao HC, Chen AC, Jeng YM, Lin CC, Tiao MM, Yang YJ, Yeung CY, Chen HL, Ni YH. Consensus statement on metabolic dysfunction-associated steatotic liver disease in children and adolescents from the joint TASL-TSPGHAN expert committee. JGH Open. [Accepted for publication].

  2. Lin YC, Wu CC, Li YE, Chen CL, Lin CR, Ni YH. Full-length 16S rRNA sequencing reveals gut microbiome signatures predictive of MASLD in children with obesity. BMC Microbiol. 2025;25(1):146.

  3. Lin YC, Liu PC, Chou FF, Hou IC, Chou CC, Chen CW, Hu SH, Chen SP, Lo HJ, Huang FF. Beliefs underlying weight control behaviors among adolescents and emerging adults living with obesity: an elicitation qualitative study. BMC Public Health. 2024;24(1):3292.

  4. Chen CL, Huang FF, Lin HF, Wu CC, Ni YH, Lin YC. Tat-beclin-1 peptide ameliorates metabolic dysfunction-associated steatotic liver disease by enhancing hepatic autophagy. Int J Mol Sci. 2024;25(22):12372.

  5. Chang PS, Chang PF, Lin YC. Usefulness of the triglyceride glucose index to predict nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2023;255:260–261.

  6. Liu PC, Lin YC, Gau BS, Tung HH, Hu SH, Chen CW. Association between lifestyle-related, psychosocial factors and obesity among female adolescents in Taiwan. J Pediatr Nurs. 2023;68:e58–e68.

  7. Lin YC, Chang PF, Ni YH. Updated upper limits of normal serum alanine aminotransferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children. J Formos Med Assoc. 2022;121:2548–2555.

  8. Chen CL, Lin YC. Autophagy dysregulation in metabolic associated fatty liver disease: a new therapeutic target. Int J Mol Sci. 2022;23(17):10055.

  9. Lin YC, Lin HF, Wu CC, Chen CL, Ni YH. Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity. J Gastroenterol. 2022;57:913–925.

  10. Lin YC, Chang PF, Liu K, Chang MH, Ni YH. Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents. J Formos Med Assoc. 2022;121:36–42.

  11. Lin YC, Wu CC, Ni YH. New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease. Front Pediatr. 2020;8:603654.

  12. Huang MJ, Lin YC, Liu K, Chang PF, Huang CS. Effects of variation status and enzyme activity for UDP-glucuronosyltransferase 1A1 gene on neonatal hyperbilirubinemia. Pediatr Neonatol. 2020;61(5):506–512.

  13. Liu HH, Lin YC, Chung CS, Liu K, Chang YH, Yang CH, Chen Y, Ni YH, Chang PF. Integrated counts of carbohydrate-active protein domains as metabolic readouts to distinguish probiotic biology and human fecal metagenomes. Sci Rep. 2019;9(1):16836.

  14. Lin YC, Chang PF, Chang MH, Ni YH. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children. Liver Int. 2018;38(7):1300–1307.

  15. Chitturi S, Wong VW, Chan WK, et al. (incl. Lin YC). The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33(1):86–98.

  16. Wong VW, Chan WK, Chitturi S, et al. (incl. Lin YC). The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85.

  17. Lin YC, Ni YH. Reply to: “Title: The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children.” J Hepatol. 2017;67(3):655–656.

  18. Lin YC, Chang PF, Lin HF, Liu K, Chang MH, Ni YH. Variants in the autophagy related gene IRGM confer susceptibility to nonalcoholic fatty liver disease by modulating lipophagy. J Hepatol. 2016;65(6):1209–1216.

  19. Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease. Int J Obes. 2015;39(8):1236–1240.

  20. Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014;99(4):869–874.

  21. Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013;97(2):326–331.

  22. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for nonalcoholic fatty liver disease in obese Taiwanese children. J Pediatr. 2011;158(5):740–744.

  23. Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC. Risk factors associated with liver steatosis in obese children and adolescents. Pediatr Neonatol. 2010;51(3):149–154.

  24. Lin YC, Chang PF, Hu FC, Chang MH, Ni YH. Variants in the UGT1A1 gene and the risk of pediatric non-alcoholic fatty liver disease. Pediatrics. 2009;124(6):e1221–e1227

 

 

[研究計畫  Research Projects – Yu-Cheng Lin]

<國科會-個人型 / NSTC Research Project Grant>

探討CD36以自噬機制調控代謝相關脂肪肝病之角色

Deciphering the role of CD36, a fatty acid transporter, in metabolic associated fatty liver disease via autophagy mechanism

<國科會-整合型 / NSTC Research Project Grant>

結合雲端技術APP、腸道菌叢檢測及多體學等先進科技探討台灣肥胖青少年非酒精性脂肪肝精準醫療的策略－開發多基因風險評分模式來預測肥胖兒童青少年對於減重介入的成效

Development of Polygenic Risk Score to Predict the Efficacy of Weight Loss Intervention in Children and Adolescents with Obesity

<114年臺北榮總暨台大醫院兩院合作研究 / 2025 TVGH–NTUH Joint Project>

揭示腸道BlautiaWexlerae的治療潛力：緩解代謝功能障礙相關脂肪肝病的機制探討

Exploring the Therapeutic Potential of Blautia wexlerae in the Gut Microbiota: Mechanistic Insights into Alleviating Metabolic Dysfunction-Associated Steatotic Liver Disease

<114年臺北榮總院內計畫 / 2025 TVGH Research Project Grant >

多巴胺第三型受體(DRD3)在代謝性脂肪肝病中的角色

Role of Dopamine Receptor D3 (DRD3) in Metabolic-Associated Fatty Liver Disease

<114年兒童肝膽疾病防治基金會計畫 / 2025 Taiwan Children Liver Foundation Grant>

Serum Metabolomics Signature for Obese Children with Metabolic Dysfunction-Associated Steatotic Liver Disease
回到最上